Revive Files Pre-IND Meeting With FDA For COVID-19 Treatment
Revive Therapeutics (CSE: RVV) this morning announced that it has filed its pre-investigational new drug (Pre-IND) meeting request with the
Read more
Technology
CloudMD Launches Flagship Telemedicine App In Ontario
CloudMD Software & Services (CSE: DOC) has officially launched its flagship telemedicine app for use in the Province of Ontario.
Read more
CloudMD Closes Financing, Raising $3.02 Million In Aggregate
CloudMD Software & Services (CSE: DOC) this morning has closed the second and final tranche of its previously announced private
Read more
Revive Seeks To Advance Bucillamine Study To Phase 2 Clinical Study
This morning, Revive Therapeutics (CSE: RVV) released an update in relation to its ongoing study of Bucillamine for the use
Read more
Revive Selects Pharm-Olam As Contract Research Organization For Infectious Disease Study
This evening, Revive Therapeutics (CSE: RVV) announced that the company has signed with a contract research organization to advance its
Read more
Revive Appoints Infectious Disease Expert As Scientific Adviser
Revive Therapeutics (CSE: RVV) this morning announced that they have appointed Dr David Boulware as scientific advisor, aimed at assisting
Read more
PowerBand Platform Development Unaffected by Pandemic
PowerBand Solutions (TSXV: PBX) announced this morning that despite the ongoing global health crisis, the pandemic is having little effect
Read more
CloudMD Sees $2.3 Million First Tranche Of Placement Close
As previously indicated, CloudMD Software & Services (CSE: DOC) has closed the first tranche of its private placement for $2.3
Read more
Revive Explores Use of Bucillamine For Infectious Disease
Revive Therapeutics (CSE: RVV) announced this morning that it has applied for a provisional patent related to that of the
Read more
Mark W. Kohler Appointed To CloudMD’s Board of Directors
CloudMD Software & Services (CSE: DOC) announced this morning that it is strengthening its Board of Directors this morning. The
Read more